Opportunity Information: Apply for PAS 08 186
Apply for PAS 08 186
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Medications Development for Polydrug Addiction Treatment (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 5, 2008 and posted on Jun 26, 2008.
- Applicants must submit their applications by Sep 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts Private institutions of higher education County governments City or township governments Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Medications Development for Polydrug Addiction Treatment (R01) funding opportunity (PAS 08 186) is a National Institutes of Health program led by the National Institute on Drug Abuse (NIDA) that focuses on discovering and developing medications for people who are addicted to more than one substance at the same time. The core problem it targets is polydrug addiction, meaning concurrent dependence on combinations such as alcohol and tobacco, alcohol and illicit drugs, prescription opioids plus other substances, or other multi-substance patterns that are common in real-world clinical populations and often make treatment more complicated. NIDA is looking for research that can move potential medications forward for these patients, with an emphasis on approaches that address the realities of overlapping substance use rather than treating each addiction in isolation.
Projects supported under this announcement are expected to be centered on medication discovery and development. The opportunity explicitly welcomes novel proposals that include clinical or preclinical testing of candidate medications, as well as the kinds of supporting research that make medication development possible, such as developing or refining animal models relevant to polydrug use and carrying out medicinal chemistry efforts to optimize promising compounds. In practice, that means applicants could propose work ranging from early-stage identification and optimization of compounds, to proof-of-concept efficacy studies in validated preclinical paradigms, to human studies when appropriate and justified. The emphasis is on producing actionable evidence that a candidate medication (or medication strategy) has potential utility for treating individuals with multiple simultaneous addictions.
The grant mechanism is the NIH Research Project Grant (R01), which is generally used for more mature, hypothesis-driven projects with substantial scope and a stronger base of preliminary data than smaller exploratory awards. This R01 opportunity runs in parallel with a companion announcement of the same scientific scope using the R21 mechanism (PAS 08 187), which is typically used for earlier-stage, high-risk or exploratory projects. Applicants would choose between R01 and R21 depending on the maturity of the idea, the amount of preliminary support, and the scale of work proposed, but the scientific focus across both is aligned around medication development for polydrug addiction.
Funding levels in the announcement are described in terms of an overall pool for Fiscal Year 2009. NIDA estimated about $3,000,000 available to support projects under this R01 announcement together with the parallel R21 announcement. Because project needs can differ widely (for example, medicinal chemistry and pharmacology optimization may require different resources than a clinical study), the agency notes that award size and duration would vary across applications. Based on expected budget ranges, the program anticipated making roughly 4 to 7 total awards in FY2009 across the combined R01 and R21 announcements, with future-year funding dependent on annual appropriations.
Eligibility is broad and includes many typical NIH applicant organizations across the public, private, nonprofit, and academic sectors. Eligible applicants include public and private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations (including small businesses), state and local governments (including counties, cities/townships, and special districts), independent school districts, and public housing authorities/Indian housing authorities. The announcement also includes a wide range of additional eligible entities such as federally recognized and other Native American tribal governments and tribal organizations, historically underrepresented and mission-focused institutions (including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities), faith-based and community-based organizations, regional organizations, US territories or possessions, and non-US (foreign) organizations.
Key administrative details are that this is a discretionary grant opportunity in the health and education domain under CFDA 93.279 (Drug Abuse and Addiction Research Programs) and it does not require cost sharing or matching. The opportunity was posted June 26, 2008, and the original and current closing date listed is September 7, 2011, with an archive date of October 8, 2011, indicating it is no longer active but remains available as a reference. The full announcement was hosted through the NIH Grants Guide (link provided in the source), and NIH Office of Extramural Research (OER) webmaster contacts were provided for access and linking issues.
Frequently Asked Questions (FAQs)
What is the Medications Development for Polydrug Addiction Treatment (R01) opportunity?
It is an NIH funding opportunity (PAS 08-186) led by the National Institute on Drug Abuse (NIDA) focused on discovering and developing medications for people who are addicted to more than one substance at the same time (polydrug addiction).
Which agency and institute lead this program?
The program is run by the National Institutes of Health (NIH) and is led by the National Institute on Drug Abuse (NIDA).
What problem is this funding opportunity trying to address?
It targets polydrug addiction, meaning concurrent dependence on multiple substances. The announcement highlights that real-world patients often use overlapping combinations of substances, which can make treatment more complicated than single-substance addiction.
What does "polydrug addiction" mean in this announcement?
Polydrug addiction refers to dependence on combinations of substances used at the same time, such as alcohol and tobacco, alcohol and illicit drugs, prescription opioids plus other substances, or other multi-substance patterns commonly seen in clinical populations.
What kinds of projects are expected to be supported?
Projects are expected to be centered on medication discovery and development for polydrug addiction. The emphasis is on moving potential medications forward for patients with multiple simultaneous addictions.
Does the opportunity support both preclinical and clinical research?
Yes. The announcement explicitly welcomes proposals that include preclinical or clinical testing of candidate medications, when appropriate and justified.
What types of supporting research are considered responsive?
In addition to testing candidate medications, the opportunity welcomes supporting work that enables medication development, including developing or refining animal models relevant to polydrug use and conducting medicinal chemistry efforts to optimize promising compounds.
How broad is the medication development pipeline that can be proposed?
The scope described ranges from early-stage identification and optimization of compounds, to proof-of-concept efficacy studies in validated preclinical paradigms, to human studies when appropriate.
What is the main emphasis when reviewing proposed work?
The emphasis is on producing actionable evidence that a candidate medication (or medication strategy) has potential utility for treating individuals with multiple simultaneous addictions, rather than treating each addiction in isolation.
What grant mechanism is used for this opportunity?
The funding mechanism is the NIH Research Project Grant (R01).
How does this R01 opportunity relate to the companion R21 opportunity?
This R01 runs in parallel with a companion announcement using the R21 mechanism (PAS 08-187). The scientific focus is aligned across both announcements around medication development for polydrug addiction.
How should an applicant choose between the R01 and the R21?
Based on the information provided, applicants choose depending on the maturity of the idea, the amount of preliminary support, and the overall scale of the work proposed. The R01 is described as more mature and hypothesis-driven with substantial scope, while the R21 is described as earlier-stage, high-risk, or exploratory.
How much funding was estimated to be available?
NIDA estimated about $3,000,000 in total for Fiscal Year 2009 to support projects under this R01 announcement together with the parallel R21 announcement.
How many awards were anticipated?
Based on expected budget ranges, the program anticipated roughly 4 to 7 total awards in FY2009 across the combined R01 and R21 announcements.
Will all awards have the same budget size and project period?
No. The agency noted that award size and duration would vary across applications because project needs can differ widely (for example, medicinal chemistry and pharmacology optimization may require different resources than a clinical study).
Is future-year funding guaranteed?
No. Future-year funding was described as dependent on annual appropriations.
Who is eligible to apply?
Eligibility is broad and includes many typical NIH applicant organizations across the public, private, nonprofit, and academic sectors, including domestic and non-US (foreign) organizations.
Are universities and colleges eligible?
Yes. The announcement lists public and private institutions of higher education as eligible applicants.
Are nonprofits eligible, including those without 501(c)(3) status?
Yes. The announcement includes nonprofits with or without 501(c)(3) status.
Are for-profit organizations eligible, including small businesses?
Yes. For-profit organizations, including small businesses, are listed as eligible applicants.
Are state and local government entities eligible?
Yes. Eligible applicants include state and local governments, including counties, cities/townships, and special districts.
Are tribal governments and tribal organizations eligible?
Yes. The announcement includes federally recognized and other Native American tribal governments and tribal organizations.
Are mission-focused and historically underrepresented institutions included in eligibility?
Yes. The announcement includes HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities.
Are faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations are listed as eligible.
Are US territories or possessions eligible?
Yes. The announcement includes US territories or possessions as eligible entities.
Are non-US (foreign) organizations eligible?
Yes. Non-US (foreign) organizations are explicitly listed as eligible.
What is the CFDA number for this opportunity?
The CFDA listed is 93.279 (Drug Abuse and Addiction Research Programs).
Is cost sharing or matching required?
No. The opportunity states that it does not require cost sharing or matching.
What type of grant is this described as?
It is described as a discretionary grant opportunity in the health and education domain.
When was the opportunity posted?
The opportunity was posted on June 26, 2008.
What were the closing and archive dates listed?
The original and current closing date listed is September 7, 2011, and the archive date is October 8, 2011.
Is this funding opportunity still active?
No. The dates indicate it is no longer active and remains available as a reference.
Where was the full announcement hosted?
The full announcement was hosted through the NIH Grants Guide (a link was provided in the source information).
Who was listed for access or linking issues related to the announcement?
NIH Office of Extramural Research (OER) webmaster contacts were provided for access and linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Medications Development for Polydrug Addiction Treatment (R21)
Previous opportunity: Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies using Cells, Tissues, and Animal Models of Disease (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAS 08 186
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAS 08 186) also looked into and applied for these:
| Funding Opportunity |
|---|
| Medications Development for Polydrug Addiction Treatment (R21) Apply for PAS 08 187 Funding Number: PAS 08 187 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integrating Biobehavioral and Sociocultural Research to Prevent HIV Transmission and Infection (R01) Apply for PA 08 188 Funding Number: PA 08 188 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Integrating Biobehavioral and Sociocultural Research to Prevent HIV Transmission and Infection (R21) Apply for PA 08 189 Funding Number: PA 08 189 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Geographic and Contextual Influences on Energy Balance Related Health Behaviors (R01) Apply for PA 08 192 Funding Number: PA 08 192 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Geographic and Contextual Influences on Energy Balance Related Health Behaviors (R21) Apply for PA 08 193 Funding Number: PA 08 193 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technological Innovations for Interdisciplinary Research Incorporating the Behavioral and Social Sciences (STTR R41/R42) Apply for PAR 08 201 Funding Number: PAR 08 201 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pilot studies in Pancreatic Cancer (R21) Apply for PA 08 208 Funding Number: PA 08 208 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| PPilot studies in Pancreatic Cancer (R03) Apply for PA 08 209 Funding Number: PA 08 209 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diet Induced Changes in Inflammation as Determinants of Colon Cancer (R01) Apply for PA 08 210 Funding Number: PA 08 210 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diet Induced Changes in Inflammation as Determinants of Colon Cancer (R21) Apply for PA 08 211 Funding Number: PA 08 211 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Prevention Intervention Research (R01) Apply for PA 08 217 Funding Number: PA 08 217 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Prevention Intervention Research (R21) Apply for PA 08 218 Funding Number: PA 08 218 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Prevention Intervention Research (R03) Apply for PA 08 219 Funding Number: PA 08 219 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Investigational Nutrigenetic Studies for Cancer Prevention (R01) Apply for PA 08 220 Funding Number: PA 08 220 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Investigational Nutrigenetic Studies for Cancer Prevention (R21) Apply for PA 08 221 Funding Number: PA 08 221 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21) Apply for PA 08 244 Funding Number: PA 08 244 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R03) Apply for RFA DA 09 019 Funding Number: RFA DA 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R01) Apply for RFA DA 09 017 Funding Number: RFA DA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical Science Oncology Centers (U54) Apply for RFA CA 09 009 Funding Number: RFA CA 09 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,250,000 |
| NINR Mentored Research Scientist Development Award for Underrepresented or Disadvantaged Investigators (K01) Apply for PAR 05 135 Funding Number: PAR 05 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $20,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAS 08 186", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.